HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• ONS: Successful early integration of palliative care requires multidisciplinary approach
• Practice patterns, not patients, may drive overutilization in oncology Lisa Hicks, MD, MSc
• Risks, benefits must be balanced when choosing optimal therapy for node-negative, HER-2–positive breast cancer Andrew D. Seidman, MD
• Researchers call for improved, unified national pediatric health policy
• Palliative medicine under the microscope: Not every patient with cancer needs palliative care Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Farydak for multiple myeloma
• FDA advisory committees to review T-VEC for metastatic melanoma treatment
• FDA approves Lenvima for progressive differentiated thyroid cancer
• FDA expands approval of Revlimid for newly diagnosed multiple myeloma
• FDA grants breakthrough therapy designation to Rintega for EGFRvIII-positive glioblastoma
• FDA grants orphan drug designation to Reolysin for pancreatic cancer
• FDA grants orphan drug designation to VS-5584 for mesothelioma
• FDA grants orphan drug status to BXQ-350 for treatment of glioblastoma multiforme
• FDA grants priority review to cobimetinib combined with Zelboraf for advanced melanoma
• Active surveillance safe for favorable-risk prostate cancer
• Bevacizumab does not hinder quality of life for women with advanced cervical cancer
• Bipolar androgen therapy benefited men with prostate cancer and no symptoms
• Cetuximab plus FOLFIRI only effective in RAS wild-type metastatic colorectal cancer
• Costly therapies for hematologic malignancies provide 'reasonable value'
• Donor leukocyte telomere length linked to transplantation outcomes in aplastic anemia
• Everolimus plus letrozole effective in recurrent endometrial carcinoma
• First-line afatinib extended OS in exon 19 deletion-positive lung adenocarcinoma
• Frailty score helps predict risk for mortality, toxicity in elderly myeloma
• Frequency of patient demands for unnecessary oncology tests overstated
• Genomic profiling provides actionable information for carcinomas of unknown primary site
• Half of US teenage girls fail to receive HPV vaccine at recommended age
• Increased coffee intake reduced risk for HCC, death from chronic liver disease in multiple ethnicities
• Integrated health care may eliminate racial disparities in colon cancer survival
• Lung-RADS may reduce false-positives in lung cancer screening
• Major bleeding rates for rivaroxaban similar in real-world, clinical trial settings
• Many older patients with early-stage breast cancer receive radiation despite limited effectiveness
• Medicaid reimbursements under ACA improved appointment availability
• Most women with breast cancer demonstrate ‘lack of understanding’ about disease
• Odds of major bleeding, mortality lower with fondaparinux than heparin
• Older donor age, nonlocal distribution potentially increase HCC recurrence after liver transplant
• Paclitaxel, trastuzumab conferred low recurrence risk in HER-2-positive breast cancer
• Patients with lymphoma can achieve long-term survival regardless of HIV status
• PET scans improve response assessment in peripheral T-cell lymphoma
• Posttransplant minimal residual disease may predict relapse for childhood ALL
• Presence of emphysema on CT scans increases lung cancer risk
• Prolonged sedentary time associated with chronic disease risks
• Radiation plus hormone therapy benefited older men with prostate cancer
• Recursive partitioning analysis forms new stages for HPV-related oropharyngeal cancer
• Researchers identify approaches to manage anticoagulant-related intracerebral hemorrhage
• Ruxolitinib superior to standard therapy for polycythemia vera
• Surgical resection effective in stage I limited-disease small cell lung cancer
• Tamoxifen reduces density, improves survival in ER-positive breast cancer
• Thyroid Cancer Care Collaborative offers paradigm to improve disease management, research
• Thyroid cancer incidence increases in all races, ethnicities
• MD Anderson researcher receives scientific award
• AACR names 11 academy fellows
• Center names chief of neuro-oncology
• Roswell Park Cancer Institute names new president, CEO
• University of Michigan cancer center appoints director
• AR-V7 status not associated with taxane chemotherapy resistance in advanced prostate cancer
• Incidence of higher-risk prostate cancer has increased since 2011
• Pembrolizumab appears safe, effective in advanced gastric cancer
• Potential HCC drug stabilized disease progression
• Risk for cancer elevated in stroke survivors
• Testicular cancer may elevate risk for intermediate- or high-risk prostate cancer